Recently, (Bridgeman et al., 2016) provide preclinical evidence that combining TKI, such as sunitinib or pazopanib, with a MEK inhibitor (MEKI) is a rationale and efficacious treatment regimen for RCC, showing a more effective suppression of tumor growth and tumor angiogenesis in vivo. This evidence concerns the gene MAP2K7 and neoplasm.